Predicting responsiveness to sorafenib: can the determination of FGF3/FGF4 amplifications enrich for clinical benefit? Academic Article uri icon

Overview

abstract

  • A small proportion of patients with advanced hepatocellular carcinoma harbor FGF3/4 gene amplifications in an 11q13 amplicon. A recent report suggests that the presence of this alteration might enrich for sensitivity to sorafenib. Further, there is growing evidence that interference with the FGF/FGFR axis has therapeutic potential in patients with advanced hepatocellular carcinoma.

publication date

  • August 1, 2014

Identity

PubMed Central ID

  • PMC4141298

Digital Object Identifier (DOI)

  • 10.3978/j.issn.2304-3881.2014.07.03

PubMed ID

  • 25202691

Additional Document Info

volume

  • 3

issue

  • 4